3SBio (HKSE:01530) Gross-Profit-to-Asset % : 29.41% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is 3SBio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. 3SBio's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$7,525 Mil. 3SBio's average Total Assets over the quarter that ended in Dec. 2023 was HK$25,592 Mil. Therefore, 3SBio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 29.41%.

3SBio Gross-Profit-to-Asset % Historical Data

The historical data trend for 3SBio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Gross-Profit-to-Asset % Chart

3SBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

30.36

28.66

29.05

26.33

28.82

3SBio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															28.67	25.28	28.53	28.06	29.41

Competitive Comparison of 3SBio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, 3SBio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3SBio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where 3SBio's Gross-Profit-to-Asset % falls into.

3SBio Gross-Profit-to-Asset % Calculation

3SBio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	7264.486	/	( (24577.732	+	25840.557)	/ 2 )
	=	7264.486	/	25209.1445
	=	28.82 %

3SBio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	7525.386	/	( (25342.802	+	25840.557)	/ 2 )
	=	7525.386	/	25591.6795
	=	29.41 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

3SBio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of 3SBio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio (HKSE:01530) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (HKSE:01530) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (HKSE:01530) Headlines

No Headlines